|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006.
|
|
3
|
Wagner AD, Grothe W, Behl S, et al:
Chemotherapy for advanced gastric cancer. Cochrane Database Syst
Rev. 2:CD0040642005.
|
|
4
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al: Phase III study of docetaxel and cisplatin plus fluorouracil
compared with cisplatin and fluorouracil as first-line therapy for
advanced gastric cancer: a report of the V325 Study Group. J Clin
Oncol. 24:4991–4997. 2006.
|
|
5
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vanhaesebroeck B, Guillermet-Guibert J,
Graupera M and Bilanges B: The emerging mechanisms of
isoform-specific PI3K signalling. Nat Rev Mol Cell Biol.
11:329–341. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paweletz CP, Charboneau L, Bichsel VE, et
al: Reverse phase protein microarrays which capture disease
progression show activation of pro-survival pathways at the cancer
invasion front. Oncogene. 20:1981–1989. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar
|
|
9
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci USA.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JW, Soung YH, Kim SY, et al: PIK3CA
gene is frequently mutated in breast carcinomas and hepatocellular
carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Campbell IG, Russell SE, Choong DY, et al:
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer
Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li VS, Wong CW, Chan TL, et al: Mutations
of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bachman KE, Argani P, Samuels Y, et al:
The PIK3CA gene is mutated with high frequency in human breast
cancers. Cancer Biol Ther. 3:772–775. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duronio V, Scheid MP and Ettinger S:
Downstream signalling events regulated by phosphatidylinositol
3-kinase activity. Cell Signal. 10:233–239. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Blume-Jensen P and Hunter T: Oncogenic
kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson DG and Walker CL: Cyclins and cell
cycle checkpoints. Annu Rev Pharmacol Toxicol. 39:295–312. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Senderowicz AM and Sausville EA:
Preclinical and clinical development of cyclin-dependent kinase
modulators. J Natl Cancer Inst. 92:376–387. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kasibhatla S and Tseng B: Why target
apoptosis in cancer treatment? Mol Cancer Ther. 2:573–580.
2003.PubMed/NCBI
|
|
22
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
23
|
Plenchette S, Filomenko R, Logette E, et
al: Analyzing markers of apoptosis in vitro. Methods Mol Biol.
281:313–331. 2004.PubMed/NCBI
|
|
24
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sartorius U, Schmitz I and Krammer PH:
Molecular mechanisms of death-receptor-mediated apoptosis.
Chembiochem. 2:20–29. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang X and Wang X: Cytochrome c promotes
caspase-9 activation by inducing nucleotide binding to Apaf-1. J
Biol Chem. 275:31199–31203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wakeling AE, Guy SP, Woodburn JR, et al:
ZD1839 (Iressa): an orally active inhibitor of epidermal growth
factor signaling with potential for cancer therapy. Cancer Res.
62:5749–5754. 2002.PubMed/NCBI
|
|
28
|
Baba A, Kawamura N, Makino H, Ohta Y,
Taketomi S and Sohda T: Studies on disease-modifying antirheumatic
drugs: synthesis of novel quinoline and quinazoline derivatives and
their anti-inflammatory effect. J Med Chem. 39:5176–5182. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rohini R, Muralidhar Reddy P, Shanker K,
Hu A and Ravinder V: Antimicrobial study of newly synthesized
6-substituted indolo[1,2-c]quinazolines. Eur J Med Chem.
45:1200–1205. 2010.PubMed/NCBI
|
|
30
|
Honkanen E, Pippuri A, Kairisalo P, Nore
P, Karppanen H and Paakkari I: Synthesis and antihypertensive
activity of some new quinazoline derivatives. J Med Chem.
26:1433–1438. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jin J, Zhu L-N, Zhang H-J, et al: XLN306
induces apoptosis in human breast carcinoma MX-1 cells. Acta Pharm
Sin B. 1:84–88. 2011. View Article : Google Scholar
|
|
32
|
Wang YK, Jin J, Zhu LN, et al: Synthesis
and antitumor activity of novel
2-(1-substituted-piperidin-4-ylamino)quinazolines as antitumor
agents. Yao Xue Xue Bao. 47:1164–1178. 2012.PubMed/NCBI
|
|
33
|
Scaduto RC Jr and Grotyohann LW:
Measurement of mitochondrial membrane potential using fluorescent
rhodamine derivatives. Biophys J. 76:469–477. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Konopleva M, Contractor R, Tsao T, et al:
Mechanisms of apoptosis sensitivity and resistance to the BH3
mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lewis JS, Meeke K, Osipo C, et al:
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer
cells resistant to estrogen deprivation. J Natl Cancer Inst.
97:1746–1759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nunez G, Benedict MA, Hu Y and Inohara N:
Caspases: the proteases of the apoptotic pathway. Oncogene.
17:3237–3245. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar
|
|
38
|
Cubedo E, Cordeu L, Bandres E, et al: New
symmetrical quinazoline derivatives selectively induce apoptosis in
human cancer cells. Cancer Biol Ther. 5:850–859. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shapiro GI and Harper JW: Anticancer drug
targets: cell cycle and checkpoint control. J Clin Invest.
104:1645–1653. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
von Bergwelt-Baildon MS, Kondo E,
Klein-Gonzalez N and Wendtner CM: The cyclins: a family of widely
expressed tumor antigens? Expert Rev Vaccines. 10:389–395.
2011.PubMed/NCBI
|
|
42
|
Goss VL, Cross JV, Ma K, Qian Y, Mola PW
and Templeton DJ: SAPK/JNK regulates cdc2/cyclin B kinase through
phosphorylation and inhibition of cdc25c. Cell Signal. 15:709–718.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Karlsson-Rosenthal C and Millar JB: Cdc25:
mechanisms of checkpoint inhibition and recovery. Trends Cell Biol.
16:285–292. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Galea CA, Wang Y, Sivakolundu SG and
Kriwacki RW: Regulation of cell division by intrinsically
unstructured proteins: intrinsic flexibility, modularity, and
signaling conduits. Biochemistry. 47:7598–7609. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chang F, Lee JT, Navolanic PM, et al:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: a target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang J, Wu A, Xu Y, Liu J and Qian X:
M(2)-A induces apoptosis and G(2)-M arrest via inhibiting PI3K/Akt
pathway in HL60 cells. Cancer Lett. 283:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yuan Q, Cai S, Zhang X, et al: A new
protoapigenone analog RY10-4 induces apoptosis and suppresses
invasion through the PI3K/Akt pathway in human breast cancer.
Cancer Lett. 324:210–220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Y, Zhang P, Qiu F, et al: Inactivation
of PI3K/Akt signaling mediates proliferation inhibition and
G2/M phase arrest induced by andrographolide in human
glioblastoma cells. Life Sci. 90:962–967. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu YZ, Zheng RL, Zhou Y, et al: Small
molecular anticancer agent SKLB703 induces apoptosis in human
hepatocellular carcinoma cells via the mitochondrial apoptotic
pathway in vitro and inhibits tumor growth in vivo. Cancer Lett.
313:44–53. 2011. View Article : Google Scholar
|
|
50
|
Sun B, Geng S, Huang X, et al: Coleusin
factor exerts cytotoxic activity by inducing
G0/G1 cell cycle arrest and apoptosis in
human gastric cancer BGC-823 cells. Cancer Lett. 301:95–105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ferreira CG, Epping M, Kruyt FA and
Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res.
8:2024–2034. 2002.PubMed/NCBI
|
|
52
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
55
|
Martelli AM, Tazzari PL, Tabellini G, et
al: A new selective AKT pharmacological inhibitor reduces
resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic
acid, and ionizing radiation of human leukemia cells. Leukemia.
17:1794–1805. 2003. View Article : Google Scholar
|
|
56
|
Hussain AR, Al-Rasheed M, Manogaran PS, et
al: Curcumin induces apoptosis via inhibition of PI3’-kinase/AKT
pathway in acute T cell leukemias. Apoptosis. 11:245–254.
2006.PubMed/NCBI
|
